(Q24199130)

English

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease

scientific article

In more languages

Statements

scholarly article

0 references

0 references

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486274&resulttype=core&format=json

14 May 2020

chronic obstructive pulmonary disease

0 references

Phillippa Poole

2

object named as

Phillippa Poole

author given names

Phillippa

author last names

Poole

1 reference

PubMed publication ID

19 October 2023

author name string

Luis Javier Nannini

1

author given names

Luis Javier

author last names

Nannini

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486274&resulttype=core&format=json

14 May 2020

PubMed publication ID

19 October 2023

Stephen J Milan

3

author given names

Stephen J

author last names

Milan

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486274&resulttype=core&format=json

14 May 2020

PubMed publication ID

19 October 2023

Annabel Kesterton

4

author given names

Annabel

author last names

Kesterton

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486274&resulttype=core&format=json

14 May 2020

PubMed publication ID

19 October 2023

language of work or name

1 reference

based on heuristic

inferred from title

publication date

30 August 2013

0 references

Cochrane Database of Systematic Reviews

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486274&resulttype=core&format=json

14 May 2020

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486274&resulttype=core&format=json

14 May 2020

CD006826

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486274&resulttype=core&format=json

14 May 2020

Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

ADRB2 polymorphisms and budesonide/formoterol responses in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Cardiovascular events in patients with COPD: TORCH study results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Adherence to inhaled therapy, mortality and hospital admission in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

The TORCH (towards a revolution in COPD health) survival study protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Inhaled corticosteroids in COPD: quantifying risks and benefits

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Immunologic aspects of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006826.PUB2

21 January 2018

Inhalation combination therapy in chronic obstructive lung disease. TRISTAN-study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23990350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/23990350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction

1 reference

https://pubmed.ncbi.nlm.nih.gov/23990350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of dry powder inhalers in COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23990350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23990350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations

1 reference

https://pubmed.ncbi.nlm.nih.gov/23990350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23990350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives

1 reference

https://pubmed.ncbi.nlm.nih.gov/23990350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of long-acting β agonists for the treatment of asthma: clearing the air.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23990350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23990350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/14651858.CD006826.PUB2

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486274&resulttype=core&format=json

14 May 2020

release_ufnkveoi6jgnxbhmvjjta66ani

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486274&resulttype=core&format=json

14 May 2020

PubMed publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486274&resulttype=core&format=json

14 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24199130&oldid=1993765296"